MOLIT contributes five presentations to the ISCB/GMDS Annual Meeting
MOLIT contributes five presentations to the ISCB/GMDS 2026 Annual Meeting in Freiburg, covering AI applications in biometrics, bioinformatics, and epidemiology…
MOLIT Now a Member of the BelWü Network
Since the middle of the year, MOLIT has been a member of BelWü, Baden-Württemberg’s high-performance research network, strengthening its IT connection…
MOLIT Now Member of the German Research Network (DFN)
Since the middle of the year, MOLIT has officially been a member of the German Research Network (DFN), one of the most powerful science networks…
MIE 2026: MOLIT at the Medical Informatics Europe in Genoa
The MOLIT Institute attended MIE 2026 in Genoa, presenting the Community Annotated Trial Search (CATS) to an international expert audience…
MOLIT at GMDS 2025: Use of Health Data
The MOLIT Data Science & AI team participated in the GMDS in Jena from September 7–10, 2025, presenting several contributions on the topic of “Use of health data”…
Together to the finish line: MOLIT & MSG at the Stimme Firmenlauf
Together as a team, eight motivated runners from MOLIT and MSG took on the 2025 STIMME Firmenlauf…
Interdisciplinary Dialogue on AI-Supported Patient Care
At a meeting of high-level representatives from ETH Zurich, University Hospital Zurich, the Max Planck Institute, SLK Clinics, the MOLIT Institute, and Heilbronn University, the focus was on the future of personalized medicine…
Knowledge exchange at the FHIR DevDays
The MOLIT Institute and MOLIT Service GmbH (MSG) at the FHIR DevDays – a leading forum for the development and application of the FHIR standard…
Heilbronn as an Innovation Hub: Launch of the I³-Lab
On September 10, the official launch of the I³-Lab in Heilbronn took place with the symbolic handover of the funding check…
MOLIT at the 6th Anniversary of the EMBL | Stanford Life Science Alliance in Heilbronn
At the EMBL | Stanford Life Science Alliance meeting, Martin Jechlinger presented how living bioprobes are opening up new paths in personalized cancer therapy…